MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

MDS Virtual Congress 2020

September 12-16, 2020. Virtual Congress. www.mdscongress.org

View by Title View Categories
Jump to:  View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z
  • O-arm stereotactic imaging in deep brain stimulation surgery workflow: A utility and cost-effectiveness analysis

    L. Furlanetti, H. Hasegawa, A. Oviedova, A. Raslan, M. Samuel, R. Selway, K. Ashkan (London, United Kingdom)

  • Object and action naming test in cognitive subtypes in nondemented patients with Parkinson´s disease

    A. Kušnírová, Z. Košutzká, M. Hajdúk, M. Králová, M. Pápayová, M. Egryová, P. Valkovič, Z. Cséfalvay (Bratislava, Slovakia)

  • Objective measurement of limb bradykinesia using marker-less tracking algorithm with 2D-video of PD patients

    J.H Shin, S.H Jeon, R. Kim, S.M Park, J.H Choi, J.N Ong, H.J Kim, B. Jeon (Seoul, Republic of Korea)

  • Objective Measurement of Muscle Mechanical Properties using a Myometric Device in People with Parkinson’s Disease in a Clinical Setting in Africa

    M. Agoriwo, P. Muckelt, C. Osei-Yeboah, B. Sankah, S. Agyapong-Badu, A. Akpalu, M. Stokes (Accra, Ghana)

  • Objective study of intra operative test for discovering optimal electrode site for effective imaging and bilateral STN-DBS stereotactic functional neurosurgery

    V. Ramaraju (Hyderabad, India)

  • Obsessive-Compulsive Characteristics in Adult Tourette Syndrome Patients with and without OCD

    D. Isaacs, H. Riordan, D. Claassen (Nashville, TN, USA)

  • Odor Identification as a Biomarker of Incident Cognitive Impairment and its Correlation with Neuropathology in the Rush MAP

    J. Toledo, J. Schneider, L. Chanine, S. Nag, R. Akhtar, A. Buchman, J. Trojanowski, D. Bennett (Houston, TX, USA)

  • Olfactory dysfunction and its relationship with clinical features of Parkinson’s disease

    Y.J Zhou, R.C He, Y.W Zhao, XX. Yan, B.S Tang, J.F Guo (Changsha, China)

  • Olfactory impairment in Wilson’s disease

    L.i Chen, X. Wang (Tianjin, China)

  • On Time, Every Time: The Effect of Cohort Ward Triage, Specialist Nursing & Admission Pre-Alert on Parkinson’s Medication Management

    S. Moore, A. Yousuf, S. Jackson (Exeter, United Kingdom)

  • On-Demand Treatment Preferences of Patients with Parkinson’s Disease and “OFF” Episodes: Heterogeneity Across Patient Subgroups

    A. Thach, J. Coulter, C. Leach, J. Sutphin, C. Mansfield (Marlborough, MA, USA)

  • Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis

    A. Lees, H. Reichmann, J.F Rocha, D. Magalhães, P. Soares-da-Silva (London, United Kingdom)

  • Open data sharing of the Parkinson’s Outcomes Project: A global, longitudinal clinical study of over 13,000 people with Parkinson’s disease

    C. Marras, A. Naito, N. Dahodwala, A. Ramirez-Zamora, M. Rafferty, M. Neault, S. Wu, J. Beck, R. DeLeon, T. Davis (Miami, FL, USA)

  • Opicapone and entacapone as add-on therapy to the treatment of infusions of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease

    J.C Martinez Castrillo, I. Parees Moreno, G. Sanchez Diez, A. Alonso Cánovas (Madrid, Spain)

  • Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis

    J. Ferreira, W. Poewe, A. Antonini, H. Gama, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Lisbon, Portugal)

  • Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study

    H. Reichmann, A. Lees, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Dresden, Germany)

  • Opicapone in fluctuating Parkinson’s disease: The daily clinical practice

    L. Armengou Garcia, G. Martí-Andrés, R. Valentí Azcárate, I. Esparragosa Vázquez, C. Toledano Illán, R. Villino Boquete, R. Luquin (Pamplona, Spain)

  • Opicapone in Parkinson’s disease – a centre’s real-life experience

    F. Carvalho, J. Silva, J. Araújo, M. Rodrigues (Braga, Portugal)

  • Opicapone management: A 2-year follow up real- life practice study

    M. Mata, C. Borrue, M. Almarcha (Madrid, Spain)

  • Opicapone study in daily clinical practice. OPRA study

    J. Abril Jaramillo, J. Rodriguez, H. Perez (Sevilla, Spain)

  • Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II

    G. Ebersbach, J. Ferreira, A. Antonini, A.T Santos, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Beelitz, Germany)

  • Optic atrophy and parkinsonism in a family associated with OPA1 mutation

    Y.T Hsu, S.P Liu, W.D Lin, C.H Tsai (Taichung, Taiwan)

  • Oral treatment of the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS) with the neuro-inflammation inhibiting compound PRI-003

    J. Post-Schulz, A. Schaffrath, A. Willuweit, D. Willbold, J. Kutzsche (Jülich, Germany)

  • Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics

    M.J Peterschmitt, T. Gurevich, T. Gasser, H. Saiki, S. Isaacson, C. Waters, A.M Wills, S. Hassin-Baer, T. Simuni, N. Hattori, S. Gaemers, S.P Sardi, S. Saubadu, P. Minini, T. Fischer (Cambridge, MA, USA)

  • Orthostatic hypotension in early onset Parkinson’s disease

    Z. Liu, D.N Su, J.H Zhou, T. Feng (Beijing, China)

  • Orthostatic hypotension in Parkinson’s disease

    L. Dommershuijsen, A. Heshmatollah, P. Koudstaal, M. Ikram, M. Ikram (Rotterdam, Netherlands)

  • Outcome Profiles in Advanced Parkinson’s Disease Patients Treated With Long-Term Levodopa-Carbidopa Intestinal Gel in a Routine Clinical Practice: Analysis From the COSMOS Study

    A. Fasano, R. García-Ramos, T. Gurevich, R. Jech, S. Femia, J. Parra, M. Simu (Toronto, ON, Canada)

  • Outcomes of a Prospective, Multicenter, International Registry of Deep Brain Stimulation for Parkinson’s Disease

    G. Deuschl, R. Jain, H. Scholtes, A. Wang, S. Paschen, M. Barbe, A. Kühn, M. Pötter-Nerger, J. Volkmann, J. Vesper (Kiel, Germany)

  • Overcoming Stimulation-Related Side Effects And Improving Outcome By Proper Programing Of Subthalamic Stimulation Of Parkinson’s Disease: Cases Report

    A. Shalash, E. Hamid, Z. Fayed (Cairo, Egypt)

Jump to:  View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley